CRF antagonists Dupont.

  • Antonio Preti
  • Published 2001 in Current opinion in investigational drugs

Abstract

DuPont (formerly DuPont Merck), Neurocrine Biosciences and Cephalon are conducting a joint investigation into corticotropin releasingfactor (CRF) ligands. These compounds may have potential as antidepressants and anxiolytics. SV-030 and other analogs from the series are entering preclinical development [361291], [362064]. 

Topics

  • Presentations referencing similar topics